News

News&Events

2020-09-29
COVID-19 Business Continuity Statement

Dear Customer,

  In this time of uncertainty, during this unprecedented COVID-19 outbreak, AventaCell is reaching out to inform all our customers that we are closely monitoring the situation, taking the necessary precautions and procedures to ensure the safety of our products, and keeping our staff safe, with a goal of maintaining global supply of our products. We are following the most conservative guidelines available from leading global and local health authorities (e.g. CDC and WHO) in keeping with achieving this goal.

  Our regional warehouses are well-stocked with product inventory in storage and are taking additional precautionary steps to ensure the safety of our products, as part of our risk management by utilizing validated gamma irradiation in our manufacturing process for our final products; for example UltraGRO™-PURE GI. Gamma irradiation is one of the most widely employed methods for pathogen reduction and commercial gamma irradiation facilities are readily accessible.

  We are also pleased to announce that UltraGRO™-PURE GI has been recognized by multiple regulatory authorities around the world to be compliant with Ancillary Material and Pathogen Reduction Treatment guidance, including;

  •  •USA FDA DMF # 34284
  •  •JAPAN PMDA Certificate
  •  •Eu. Phr. 5.2.12.4 Compliance

  As your partner in cell production, we aim to support you in these challenging times to avoid interruption to your cell research and development plans. If you have any questions, please contact our Customer Service Team or your local Distributor. Thank you for your support of AventaCell BioMedical Corp. Ltd. by choosing to use our products.

  We wish safety and health to you and your families.

  Sincerely